127 related articles for article (PubMed ID: 37916464)
1. Cerebrospinal fluid pleocytosis is associated with HIV-1 neuroinvasion during acute infection.
Chan P; Moreland S; Sacdalan C; Kroon E; Colby D; Sriplienchan S; Pinyakorn S; Phanuphak N; Jagodzinski L; Valcour V; Vasan S; Paul R; Trautmann L; Spudich S;
AIDS; 2024 Mar; 38(3):373-378. PubMed ID: 37916464
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment.
Spudich SS; Nilsson AC; Lollo ND; Liegler TJ; Petropoulos CJ; Deeks SG; Paxinos EE; Price RW
BMC Infect Dis; 2005 Nov; 5():98. PubMed ID: 16266436
[TBL] [Abstract][Full Text] [Related]
3. Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study.
Livelli A; Vaida F; Ellis RJ; Ma Q; Ferrara M; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; McCutchan JA; Morgello S; Sacktor N; Simpson DM; Grant I; Letendre SL;
Lancet HIV; 2019 Jul; 6(7):e456-e462. PubMed ID: 31208949
[TBL] [Abstract][Full Text] [Related]
4. Herpes zoster in HIV-1 infection: The role of CSF pleocytosis in secondary CSF escape and discordance.
Hagberg L; Price RW; Zetterberg H; Fuchs D; Gisslén M
PLoS One; 2020; 15(7):e0236162. PubMed ID: 32697807
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal Fluid Viral Load Across the Spectrum of Untreated Human Immunodeficiency Virus Type 1 (HIV-1) Infection: A Cross-Sectional Multicenter Study.
Ulfhammer G; Edén A; Antinori A; Brew BJ; Calcagno A; Cinque P; De Zan V; Hagberg L; Lin A; Nilsson S; Oprea C; Pinnetti C; Spudich S; Trunfio M; Winston A; Price RW; Gisslén M
Clin Infect Dis; 2022 Aug; 75(3):493-502. PubMed ID: 34747481
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load.
Peluso MJ; Ferretti F; Peterson J; Lee E; Fuchs D; Boschini A; Gisslén M; Angoff N; Price RW; Cinque P; Spudich S
AIDS; 2012 Sep; 26(14):1765-74. PubMed ID: 22614889
[TBL] [Abstract][Full Text] [Related]
7. Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy.
Marra CM; Maxwell CL; Collier AC; Robertson KR; Imrie A
BMC Infect Dis; 2007 May; 7():37. PubMed ID: 17475004
[TBL] [Abstract][Full Text] [Related]
8. Distribution of Human Immunodeficiency Virus (HIV) Ribonucleic Acid in Cerebrospinal Fluid and Blood Is Linked to CD4/CD8 Ratio During Acute HIV.
Chan P; Patel P; Hellmuth J; Colby DJ; Kroon E; Sacdalan C; Pinyakorn S; Jagodzinski L; Krebs S; Ananworanich J; Valcour V; Spudich S;
J Infect Dis; 2018 Aug; 218(6):937-945. PubMed ID: 29741638
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid pleocytosis as a predictive factor for CSF and plasma HIV RNA discordance and escape.
de Almeida SM; Rotta I; de Pereira AP; Tang B; Umlauf A; Ribeiro CEL; Letendre S; Ellis RJ;
J Neurovirol; 2020 Apr; 26(2):241-251. PubMed ID: 32002817
[TBL] [Abstract][Full Text] [Related]
10. Asymptomatic Cerebrospinal Fluid HIV-1 Viral Blips and Viral Escape During Antiretroviral Therapy: A Longitudinal Study.
Edén A; Nilsson S; Hagberg L; Fuchs D; Zetterberg H; Svennerholm B; Gisslén M
J Infect Dis; 2016 Dec; 214(12):1822-1825. PubMed ID: 27683820
[TBL] [Abstract][Full Text] [Related]
11. Diffuse White Matter Signal Abnormalities on Magnetic Resonance Imaging Are Associated With Human Immunodeficiency Virus Type 1 Viral Escape in the Central Nervous System Among Patients With Neurological Symptoms.
Kugathasan R; Collier DA; Haddow LJ; El Bouzidi K; Edwards SG; Cartledge JD; Miller RF; Gupta RK
Clin Infect Dis; 2017 Apr; 64(8):1059-1065. PubMed ID: 28329096
[TBL] [Abstract][Full Text] [Related]
12. Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection.
Ananworanich J; Sacdalan CP; Pinyakorn S; Chomont N; de Souza M; Luekasemsuk T; Schuetz A; Krebs SJ; Dewar R; Jagodzinski L; Ubolyam S; Trichavaroj R; Tovanabutra S; Spudich S; Valcour V; Sereti I; Michael N; Robb M; Phanuphak P; Kim JH; Phanuphak N
J Virus Erad; 2016; 2(1):43-48. PubMed ID: 26889497
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid HIV-1 RNA levels in asymptomatic patients with early stage chronic HIV-1 infection: support for the hypothesis of local virus replication.
García F; Niebla G; Romeu J; Vidal C; Plana M; Ortega M; Ruiz L; Gallart T; Clotet B; Miró JM; Pumarola T; Gatell JM
AIDS; 1999 Aug; 13(12):1491-6. PubMed ID: 10465072
[TBL] [Abstract][Full Text] [Related]
14. Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma.
Soulie C; Grudé M; Descamps D; Amiel C; Morand-Joubert L; Raymond S; Pallier C; Bellecave P; Reigadas S; Trabaud MA; Delaugerre C; Montes B; Barin F; Ferré V; Jeulin H; Alloui C; Yerly S; Signori-Schmuck A; Guigon A; Fafi-Kremer S; Haïm-Boukobza S; Mirand A; Maillard A; Vallet S; Roussel C; Assoumou L; Calvez V; Flandre P; Marcelin AG;
J Antimicrob Chemother; 2017 Aug; 72(8):2351-2354. PubMed ID: 28472307
[TBL] [Abstract][Full Text] [Related]
15. Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study.
García F; Alonso MM; Romeu J; Knobel H; Arrizabalaga J; Ferrer E; Dalmau D; Ruiz I; Vidal F; Frances A; Segura F; Gomez-Sirvent JL; Cruceta A; Clotet B; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
J Acquir Immune Defic Syndr; 2000 Sep; 25(1):26-35. PubMed ID: 11064501
[TBL] [Abstract][Full Text] [Related]
16. Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation.
Dahl V; Peterson J; Fuchs D; Gisslen M; Palmer S; Price RW
AIDS; 2014 Sep; 28(15):2251-8. PubMed ID: 25022595
[TBL] [Abstract][Full Text] [Related]
17. Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden.
Spudich S; Gisslen M; Hagberg L; Lee E; Liegler T; Brew B; Fuchs D; Tambussi G; Cinque P; Hecht FM; Price RW
J Infect Dis; 2011 Sep; 204(5):753-60. PubMed ID: 21844301
[TBL] [Abstract][Full Text] [Related]
18. Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection.
Sinclair E; Ronquillo R; Lollo N; Deeks SG; Hunt P; Yiannoutsos CT; Spudich S; Price RW
J Acquir Immune Defic Syndr; 2008 Apr; 47(5):544-52. PubMed ID: 18362693
[TBL] [Abstract][Full Text] [Related]
19. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.
Canestri A; Lescure FX; Jaureguiberry S; Moulignier A; Amiel C; Marcelin AG; Peytavin G; Tubiana R; Pialoux G; Katlama C
Clin Infect Dis; 2010 Mar; 50(5):773-8. PubMed ID: 20100092
[TBL] [Abstract][Full Text] [Related]
20. Single-copy assay quantification of HIV-1 RNA in paired cerebrospinal fluid and plasma samples from elite controllers.
Dahl V; Peterson J; Spudich S; Lee E; Shacklett BL; Price RW; Palmer S
AIDS; 2013 Apr; 27(7):1145-9. PubMed ID: 23211774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
